Effect of initiating statin therapy on long-term outcomes of patients with dyslipidemia after intracerebral hemorrhage

Lin, Ming‐Shyan; Lin, Yu‐Sheng; Chang, Shih-Tai; Wang, Po‐Chang; Wu, Victor Chien‐Chia; Lin, Wen−Piao; Chung, Chang-Min

doi:10.1016/j.atherosclerosis.2019.07.009

Cited by 20 publications

(29 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 665 citations were identified, and 210 potentially eligible articles were retrieved in full text. Overall, 54 studies were included in the review ( Figure 1 ) [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 ]. Risk of bias assessment using NOS showed that the studies have low risk of bias.…”

Section: Resultsmentioning

confidence: 99%

Effect of Statins on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis of Propensity Score-Matched Studies

Nowak¹,

Niemczyk

Florczyk³

et al. 2022

JCM

View full text Add to dashboard Cite

Statins are lipid-lowering medications used for the prevention of cardiovascular disease (CVD), but the pleiotropic effects of statins might be beneficial in other chronic diseases. This meta-analysis investigated the association between statin use and mortality in different chronic conditions. Eligible studies were real-world studies that compared all-cause mortality over at least 12 months between propensity score-matched statin users and non-users. Overall, 54 studies were included: 21 in CVD, 6 in chronic kidney disease, 6 in chronic inflammatory diseases, 3 in cancer, and 18 in other diseases. The risk of all-cause mortality was significantly reduced in statin users (hazard ratio: 0.72, 95% confidence interval: 0.66–0.76). The reduction in mortality risk was similar in CVD studies (0.73, 0.66–0.76) and non-CVD studies (0.70, 0.67–0.79). There were no significant differences in the risk reduction between cohorts with different diseases (p = 0.179). The greatest mortality reduction was seen in studies from Asia (0.61, 0.61–0.73) and the lowest in studies from North America (0.78, 0.73–0.83) and Australia (0.78, 0.62–0.97). There was a significant heterogeneity (I2 = 95%, tau2 = 0.029, p < 0.01). In conclusion, statin use was associated with a significantly reduced risk of all-cause mortality in real-world cohorts with CVD and non-CVD.

show abstract

Section: Resultsmentioning

confidence: 99%

Effect of Statins on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis of Propensity Score-Matched Studies

Nowak¹,

Niemczyk

Florczyk³

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…A total of 49027 patients were included, with 8094 patients on statin therapy and 40933 patients in a control group. Among all included studies, eight were observational [14,18,[20][21][22][23][24][25], while 1 was a post-hoc analysis of RCT [19]. The follow-up period of included studies ranged from 6 months to 120 months.…”

Section: Figure 1: Prisma Flowchart Of Selection Of Studiesmentioning

confidence: 99%

“…Seven studies compared all-cause mortality between ICH patients who received statins and those who did not [14,[18][19][20][21][22]25]. The overall all-cause mortality rate was 29.13%, and no significant difference was found between the two study groups (RR: 0.80, 95% CI: 0.53-1.20, p-value: 0.27).…”

Section: Risk Of All-cause Mortalitymentioning

confidence: 99%

See 1 more Smart Citation

Effect of Statin Therapy on Mortality and Recurrence of Intracerebral Hemorrhage in Patients With Spontaneous Intracerebral Hemorrhage

Jamil¹,

Batool²,

Shaik³

et al. 2022

Cureus

View full text Add to dashboard Cite

Statins can play an essential role in the tertiary and primary prevention of cardiovascular events by reduction of cholesterol in a stroke patient. This meta-analysis aims to assess statin therapy's effect on mortality and recurrence of Intracranial Hemorrhage (ICH) in patients with spontaneous ICH. The current meta-analysis was conducted following Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) guidelines. A systematic search was performed using PubMed, EMBASE, and Cochrane Library to identify studies assessing the use of statins in patients with ICH. The primary outcome assessed in the current meta-analysis was a hemorrhagic stroke. The secondary outcomes included cardiac-related events and all-cause mortality. A total of 9 studies were included in the current meta-analysis enrolling 49027 patients, with 8094 patients on statin therapy and 40933 patients in the control group. The risk of recurrent ICH was significantly lower in patients receiving stains (RR: 0.81, 95% CI: 0.67-0.99, p-value: 0.02) compared to placebo. However, no significant differences were observed regarding all-cause mortality (RR: 0.80, 95% CI: 0.53-1.20, p-value: 0.27) and cardiovascular events (RR: 1.24, 95% CI: 0.88-1.74). In ICH patients, statins can reduce the risk of recurrent ICH in patients with a history of ICH. However, statins had no significant effect on all-cause mortality and cardiovascular events.

show abstract

“…Cohort studies have revealed that statins could reduce by threefold the odds of mortality in patients diagnosed with ICH 6 . A large‐scale study ( n = 17,980) based on the National Health Insurance Research Database in Taiwan also showed that patients prescribed with statins after ICH had a lower risk of all‐cause mortality and cardiovascular death 7 . Currently, there is no consensus regarding the effect of statin use prior to ICH 8 .…”

Section: Introductionmentioning

confidence: 99%

Prior statin and short‐term outcomes of primary intracerebral hemorrhage: From a large‐scale nationwide longitudinal registry

Wang

Xiong

et al. 2022

CNS Neurosci Ther

View full text Add to dashboard Cite

Introduction:The relationship between statins and intracerebral hemorrhage outcomes is unclear. Aim:We aimed to compare the in-hospital mortality and evacuation of intracranial hematoma rates in patients with primary intracerebral hemorrhage between prior statin users and nonusers. Results:The final study population included 66,263 patients. Multivariable logistics analyses showed that prior statin use was not associated with in-hospital mortality for primary intracerebral hemorrhage (adjusted odd ratio 0.78, 95% CI 0.61-1.01), but reduced the proportion of patients undergoing evacuation of intracranial hematoma (adjusted odd ratio 0.70, 95% CI 0.61-0.82). Propensity score matching analyses yielded similar results. Conclusion:Prior statin use was not associated with in-hospital mortality but did reduce evacuation of intracranial hematoma rates.

show abstract

Effect of initiating statin therapy on long-term outcomes of patients with dyslipidemia after intracerebral hemorrhage

Cited by 20 publications

References 35 publications

Effect of Statins on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis of Propensity Score-Matched Studies

Effect of Statins on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis of Propensity Score-Matched Studies

Effect of Statin Therapy on Mortality and Recurrence of Intracerebral Hemorrhage in Patients With Spontaneous Intracerebral Hemorrhage

Prior statin and short‐term outcomes of primary intracerebral hemorrhage: From a large‐scale nationwide longitudinal registry

Contact Info

Product

Resources

About